Skip to main content

Packaging, labelling and marketing of pharmaceuticals has evolved rapidly in India, with concerns about ‘deceptive similarity’ at the helm. Our Pharma Dossier (Vol. 1) discusses trade mark jurisprudence in light of the primary factor – the consumer.

Whereas differentiation on the basis of a name may have become more constrictive, creative use of unconventional marks and branding exercises by pharmaceutical companies has aided the creation of unique identities. Useful, with the rate e-pharmacies are disrupting traditional distribution models.

 

To read more, contact us at email@anandandanand.com

Most Recent

News & Insights

VIEW ALL
News & Updates
Nov 04, 2025

In a remarkable conclusion to one of India’s longest-running trademark disputes, the order authored by Justice Sanjeev Narula of the Hon’ble High Court

DELHI HIGH COURT BRINGS 25-YEAR “CELEBRATIONS” TRADEMARK DISPUTE TO A WHOLESOME CLOSE
News & Updates
Nov 02, 2025

Partner Litigation, Dhruv Anand, spoke to Times of India for its dive-deep article on ‘Stars v AI’ giving a 360 degree roundup of what actually makes

Stars vs AI: Dhruv Anand speaks to ToI about personality rights and the intent behind protecting them
Thought Leadership
Oct 22, 2025

‘First published on Lexology’ By: Pravin Anand, Vaishali R Mittal and Siddhant Chamola A. INTRODUCTION Standards‑essential patents (“SEPs”)

Interim Licences vs Anti Interim Injunctions: a Cross Border Stand Off
Thought Leadership
Oct 16, 2025

‘First published on Lexology’ By: Safir Anand and Omesh Puri The Office of the Controller General of Patents, Designs, and Trade Marks has issued a

Indian Trade Marks Office issues Office Order – Streamlining Registry Function